Neuralink's 26 Patients vs. Synchron's 15: The $9.7 Billion Brain Implant Race
Neuralink has 26 patients, $1.3B in funding and a $9.7B valuation, but Synchron's less invasive Stentrode may win FDA clearance first. China already has a commercial BCI.
Topic
Topic
Neuralink has 26 patients, $1.3B in funding and a $9.7B valuation, but Synchron's less invasive Stentrode may win FDA clearance first. China already has a commercial BCI.